Silvia Lopez-Fernandez
Overview
Explore the profile of Silvia Lopez-Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dobarro D, Raposeiras-Roubin S, Almenar-Bonet L, Sole-Gonzalez E, Padilla-Lopez M, Diez-Lopez C, et al.
Life (Basel)
. 2025 Jan;
14(12.
PMID: 39768278
Heart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive...
2.
Dominguez F, Uribarri A, Larranaga-Moreira J, Ruiz-Guerrero L, Pastor-Pueyo P, Gayan-Ordas J, et al.
Rev Esp Cardiol (Engl Ed)
. 2024 May;
77(8):667-679.
PMID: 38763214
Myocarditis is defined as myocardial inflammation and its etiology is highly diverse, including infectious agents, drugs, and autoimmune diseases. The clinical presentation also varies widely, extending beyond the classic clinical...
3.
Morales-Garcia M, Fernandez-Sanchez J, Lopez-Munoz J, Lopez-Fernandez S, Plaza Carrera J
Eur Heart J Cardiovasc Imaging
. 2023 Nov;
25(3):e112.
PMID: 37922493
No abstract available.
4.
Esteban-Fernandez A, Gomez-Otero I, Lopez-Fernandez S, Rodriguez Santamarta M, Pastor-Perez F, Fluvia-Brugues P, et al.
Clin Res Cardiol
. 2023 Jun;
113(8):1171-1182.
PMID: 37341769
Aims: Heart failure (HF) guidelines recommend treating all patients with HF and reduced ejection fraction (HFrEF) with quadruple therapy, although they do not establish how to start it. This study...
5.
Dobarro D, Donoso-Trenado V, Sole-Gonzalez E, Moliner-Abos C, Garcia-Pinilla J, Lopez-Fernandez S, et al.
ESC Heart Fail
. 2023 Jan;
10(2):1193-1204.
PMID: 36655614
Aim: Patients with advanced heart failure (AHF) who are not candidates to advanced therapies have poor prognosis. Some trials have shown that intermittent levosimendan can reduce HF hospitalizations in AHF...
6.
Esteban-Fernandez A, Ortiz Cortes C, Lopez-Fernandez S, Recio Mayoral A, Camacho Jurado F, Gomez Otero I, et al.
ESC Heart Fail
. 2022 Jun;
9(5):3071-3078.
PMID: 35748119
Aims: Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help...
7.
Delgado-Jimenez J, Segovia-Cubero J, Almenar-Bonet L, de Juan-Baguda J, Lara-Padron A, Garcia-Pinilla J, et al.
J Clin Med
. 2022 Mar;
11(5).
PMID: 35268260
Hyperkalaemia is a growing concern in the treatment of patients with heart failure and reduced ejection fraction (HFrEF) as it limits the use of some prognostic-modifying drugs and has a...
8.
Oyanguren J, Diaz-Molina B, Lekuona I, Gonzalez-Costello J, Lopez-Fernandez S, Garcia-Pinilla J, et al.
Rev Esp Cardiol (Engl Ed)
. 2021 Dec;
75(8):636-648.
PMID: 34903479
Introduction And Objectives: Optimal medical therapy decreases mortality and heart failure (HF) hospitalizations in HF patients with reduced left ventricular ejection fraction. Women have been underrepresented in clinical trials and...
9.
Segura-Rodriguez D, Bermudez-Jimenez F, Gonzalez-Camacho L, Moreno Escobar E, Garcia-Orta R, Alcala-Lopez J, et al.
Front Cardiovasc Med
. 2021 Dec;
8:748003.
PMID: 34869653
Arrhythmogenic cardiomyopathy (AC) is a life-threatening disease which predispose to malignant arrhythmias and sudden cardiac death (SCD) in the early stages of the disease. Risk stratification relies on the electrical,...
10.
Segura-Rodriguez D, Bermudez-Jimenez F, Carriel V, Lopez-Fernandez S, Gonzalez-Molina M, Oyonarte Ramirez J, et al.
Eur Heart J Cardiovasc Imaging
. 2019 Nov;
21(4):378-386.
PMID: 31702781
Aims: Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a life-threatening entity with a highly heterogeneous genetic background. Cardiac magnetic resonance (CMR) imaging can identify fibrofatty scar by late gadolinium enhancement (LGE)....